Share Prices & Company Research

Market News

07 Dec 2021 | 12:56

Medicago and GSK's Covid-19 vaccine shows 75.3% efficacy against Delta strain

(Sharecast News) - Medicago and GSK's Covid-19 vaccine showed a high degree of efficacy in blocking symptomatic disease in those infected with the Delta strain of SARS-CoV-2. The company highlighted the fact that most other published results were for trials that had taken place when only the "ancestral" virus was circulating, so that direct comparisons between the results were "impossible".

"This is an incredible moment for Medicago and for novel vaccine platforms. The results of our clinical trials show the power of plant-based vaccine manufacturing technology," said Takashi Nagao, CEO and President at Medicago.

"If approved, we will be contributing to the world's fight against the COVID-19 pandemic with the world's first plant-based vaccine for use in humans."

According to Quebec-based Medicago, the phase three clinical trial results of its adjuvanted plant-based vaccine proved the efficacy of the shot against all variants.

Against Delta specifically, it showed 75.3% efficacy, was well-tolerated and no related serious adverse events were reported among the trial participants who received the shot.

Efficacy versus all variants was 71.0%.

A submission for final regulatory approval from Health Canada would be filed immediately.

The trial into Medicago's plant-based vaccine, in conjunction with GSK's pandemic adjuvant, was conducted among 24,000 persons 18 years of age or older from six different countries.

The Omicron variant of the SARS-CoV-2 virus was not circulating during the study.

As of 1240 GMT, shares of GSK were 0.67% higher at 1,565.20p.



Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 17th May 2022
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.